Real-world use of ticagrelor versus clopidogrel in percutaneous coronary intervention-treated ST-elevation myocardial infarction patients: A single-center registry study
ConclusionTicagrelor was preferred in low bleeding risk patients, which may have contributed to less BARC 3–5 bleeding and lower mortality for T-DAPT. Thus, bleeding mitigation is a clinical priority when selecting DAPT for PCI-treated STEMI patients. Continuation of initial DAPT regimen was typical, but early switching from clopidogrel to ticagrelor shows willingness to optimize DAPT. Patients with very low CRUSADE scores (<21.5) may be appropriate for switching to a potent P2Y12 inhibitor.
Source: Journal of the Saudi Heart Association - Category: Cardiology Source Type: research
More News: Academia | Angioplasty | Australia Health | Bleeding | Cardiology | Clopidogrel | Coronary Angioplasty | Diabetes | Endocrinology | Heart | Heart Attack | Middle East Health | Percutaneous Coronary Intervention | Plavix | Saudi Arabia Health | Study